469 related articles for article (PubMed ID: 17541983)
1. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
2. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
3. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
Krymskaya VP
Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
[TBL] [Abstract][Full Text] [Related]
4. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
5. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
7. A patient with TSC1 germline mutation whose clinical phenotype was limited to lymphangioleiomyomatosis.
Sato T; Seyama K; Kumasaka T; Fujii H; Setoguchi Y; Shirai T; Tomino Y; Hino O; Fukuchi Y
J Intern Med; 2004 Aug; 256(2):166-73. PubMed ID: 15257730
[TBL] [Abstract][Full Text] [Related]
8. [Current understanding and perspectives of lymphangioleiomyomatosis].
Seyama K; Ando K; Hoshika Y; Suzuki Y; Takekawa H
Nihon Rinsho; 2013 Jun; 71(6):1103-8. PubMed ID: 23855221
[TBL] [Abstract][Full Text] [Related]
9. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
10. Multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis with a TSC2 gene.
Maruyama H; Seyama K; Sobajima J; Kitamura K; Sobajima T; Fukuda T; Hamada K; Tsutsumi M; Hino O; Konishi Y
Mod Pathol; 2001 Jun; 14(6):609-14. PubMed ID: 11406664
[TBL] [Abstract][Full Text] [Related]
11. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
[TBL] [Abstract][Full Text] [Related]
12. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.
Carsillo T; Astrinidis A; Henske EP
Proc Natl Acad Sci U S A; 2000 May; 97(11):6085-90. PubMed ID: 10823953
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
16. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
17. The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis.
Strizheva GD; Carsillo T; Kruger WD; Sullivan EJ; Ryu JH; Henske EP
Am J Respir Crit Care Med; 2001 Jan; 163(1):253-8. PubMed ID: 11208653
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
19. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
20. Lymphangioleiomyomatosis: A review.
Hohman DW; Noghrehkar D; Ratnayake S
Eur J Intern Med; 2008 Jul; 19(5):319-24. PubMed ID: 18549932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
